Redeye comments on AVTECH’s Q3 2023, which was slightly below on topline and EBITDA.
Q3 confirms that Vitrolife is going through a period with softer organic growth, even below our expe...
Redeye states that the Q3 report came in below estimates on top-line - caused by continued destockin...
Redeye think that Sdiptech’s Q3 report was stronger than our expectations, with both Resource Effici...
- Q3 org growth -8% (ABGe -7%), 1% adj. EBITA beat on lower costs - Operating cash flow at SEK 133m ...
- Adj. EBITA SEK 22.9m (+8% vs. ABGSCe 21.3m) - Q3 numbers imply +2% adj.
- Net sales SEK 432m, 1% vs ABGSCe - EBITA SEK 59m, 52% vs ABGSCe - Announced acquisition of Thebalu...
Redeye comments on the Q3 report released earlier this morning.
Redeye thinks the Q3 report from Truecaller was weaker than anticipated, particularly the monetizati...
Redeye sees a solid Q3 report from Proact despite sales and EBITA coming in slightly short of our ex...
Q3 EBIT of SEK 33m, 25% below ABGSC forecast AUM up 6% q-o-q, strengthen by Aquila Group transaction...
Redeye recognizes a solid Q3 report from Stille, which unveiled nuggets such as 18% y/y sales growth...
We lower '23e-'25e adj. EBITA by 5-1% B3's lowered '25 targets offset by cost-savings programme '23e...
We raise '23e-'25e adj. EBITA by 9-2% Expect further discontinuations Trading at '23e-'24e EV/EBITA ...
Redeye thinks the Q3 report was weaker than expected.
Redeye updates on Invisio following the company’s Q3-results which saw stronger topline than expecte...
Redeye comments on the third quarter report of BioInvent.
NOI and Rec PTP +2% and -2%, respectively, vs ABGSCe Limited net letting, flat occupancy, strong mar...
Redeye provides an update following the Q3 report. The rolling 12-month net sales increased by 16.
Redeye updates its view on Artificial Solutions (AS) on the back of its Q3 2023 report.
